Mortality and Its Determinants in People With Psychotic Disorder
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We investigated mortality and its determinants in people with psychotic disorder. METHODS: A nationally representative two-stage cluster sample of 8028 persons aged 30 years or older from Finland was selected for a comprehensive health survey conducted from 2000 to 2001. Participants were screened for psychotic disorder, and screen-positive persons were invited for a Structured Clinical Interview for DSM-IV. The diagnostic assessment of DSM-IV psychotic disorders was based on the Structured Clinical Interview for DSM-IV, case records from mental health treatments, or both. Mortality was followed up until September 2009 and analyzed using Cox proportional hazards model. RESULTS: People with schizophrenia (hazard ratio [HR] = 3.03; 95% confidence interval [CI] = 1.93-4.77) and other nonaffective psychoses (HR = 1.84; 95% CI = 1.17-2.91) had elevated mortality risk, whereas people with affective psychoses did not (HR = 0.61; 95% CI = 0.24-1.55). Antipsychotic medication use was associated with increased mortality (HR = 2.34; 95% CI = 1.86-2.96). There was an interaction between antipsychotic medication use and the presence of a psychotic disorder: antipsychotic medication use was only associated with elevated mortality in persons who were using antipsychotics and did not have primary psychotic disorder. In persons with psychotic disorder, mortality was predicted by smoking and Type 2 diabetes at baseline survey. CONCLUSIONS: Schizophrenia and nonaffective psychoses are associated with increased mortality risk, whereas affective psychoses are not. Antipsychotic medication use increases mortality risk in older people without primary psychotic disorder, but not in individuals with schizophrenia. Smoking and Type 2 diabetes are important predictors of elevated mortality risk in persons with psychotic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · cited 1×
“Although schizophrenia and other psychotic disorders are associated with several health problems, such as Type 2 diabetes (10,11), metabolic syndrome (11,12), obesity (11,13), and poor physical condition (14), the contribution of these to excess mortality is largely unknown.”
BackgroundSaha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 2×
“In contrast, antipsychotic use in older people is associated with excess mortality (19,20).”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052827 · Cited by 959
Chang, C.-K., Hayes, R. D., Perera, G., Broadbent, M. T. M., Fernandes, A. C., Lee, W. E., Hotopf, M., & Stewart, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019590 · Cited by 714 · cited 1×
“Previous studies have reported elevated mortality in schizoaffective disorder (3,40), whereas ONAP have been studied much less.”
BackgroundWittchen, H.-U., Lachner, G., Wunderlich, U., & Pfister, H. (1998) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270050095 · Cited by 668 · cited 2×
“Wittchen HU, Lachner G, Wunderlich U, Pfister H. Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI).”
MethodOsborn, D. P. J., Levy, G., Nazareth, I., Petersen, I., Islam, A., & King, M. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.242 · Cited by 608 · cited 2×
“Consistently with previous studies, antipsychotic medication use did not explain the elevated mortality risk (5,7), but no protective effect of antipsychotic medication was observed either.”
ResultTwenty-five year mortality of a community cohort with schizophrenia
Brown, S., Kim, M., Mitchell, C., & Inskip, H. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067512 · Cited by 601 · cited 4×
“The proportion of natural deaths increases over time (2,6), with circulatory and respiratory diseases being the most important causes of excess mortality (1Y4,6Y8).”
BackgroundResultInfluentialLaursen, T. M., Munk-Olsen, T., Nordentoft, M., & Mortensen, P. B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0612 · Cited by 380 · cited 2×
“Previous studies have reported elevated mortality in schizoaffective disorder (3,40), whereas ONAP have been studied much less.”
BackgroundResultMental disorders and cause-specific mortality
Joukamaa, M., HeliöVaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.498 · Cited by 328
The impact of substance use disorders on the course of schizophrenia—A 15-year follow-up study
Schmidt, L. M., Hesse, M., & Lykke, J. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.011 · Cited by 171 · cited 7×
“Possible clinical predictors of mortality were global outcome based on the Major Symptoms of Schizophrenia Scale, which was categorized as good (recovery or mild deterioration) versus poor (moderate or marked deterioration), and DSM-IV alcohol or substance abuse or dependence (substance use disorder [SUD]).”
BackgroundInfluentialCigarette smoking and mortality risk in people with schizophrenia
Kelly, D. L., McMahon, R. P., Wehring, H. J., Liu, F., Mackowick, K. M., Boggs, D. L., Warren, K. R., Feldman, S., Shim, J.-C., Love, R. C., et al. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp152 · Cited by 158 · cited 3×
“Smoking is one of the identified determinants of excess mortality in people with schizophrenia (6,8,9).”
BackgroundResultSuvisaari, J., Perälä, J., Saarni, S. I., Härkänen, T., Pirkola, S., Joukamaa, M., Koskinen, S., Lönnqvist, J., & Reunanen, A. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0762-y · Cited by 68 · cited 4×
“However, this is consistent with previous findings from this study: people with affective psychoses did not differ from the general population in the prevalence of Type 2 diabetes and other metabolic comorbidities (10,12), neither in their physical condition and functional capacity (14,42).”
BackgroundMethodResultSelf-citationViertiö, S., Tuulio-Henriksson, A., Perälä, J., Saarni, S. I., Koskinen, S., Sihvonen, M., Lönnqvist, J., & Suvisaari, J. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2010.12.005 · Cited by 58 · cited 1×
“However, this is consistent with previous findings from this study: people with affective psychoses did not differ from the general population in the prevalence of Type 2 diabetes and other metabolic comorbidities (10,12), neither in their physical condition and functional capacity (14,42).”
ResultSelf-citation
Cited by
Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1314 · Cited by 384
Ringen, P. A., Engh, J. A., Birkenaes, A. B., Dieset, I., & Andreassen, O. A. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00137 · Cited by 339
Severance, E. G., Gressitt, K. L., Stallings, C. R., Origoni, A. E., Khushalani, S., Leweke, F. M., Dickerson, F. B., & Yolken, R. H. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.018 · Cited by 243
Causes of mortality in schizophrenia: an updated review of European studies
Department of Psychiatry, W. M. U., Piotrowski, P., M. Gondek, T., Department of Psychiatry, W. M. U., Królicka-Deręgowska, A., Department of Psychiatry, W. M. U., Misiak, B., Department of Genetics, W. M. U., Adamowski, T., Department of Nervous System Diseases, F. O. H. S., et al. (2017) · Psychiatria Danubina · doi:10.24869/psyd.2017.108 · Cited by 107
“Although the Finnish study showed that any antipsychotics therapy was associated with increased general mortality (HR=2.34; 95%CI=1.86–2.96) versus untreated people, yet treatment of people with psychotic disorder did not significantly increase a mortality risk (HR=1.08; 95% CI=0.58–2.00) (Suvisaari et al. 2013).”
BackgroundInfluentialMortality in schizophrenia: clinical and serological predictors
Dickerson, F., Stallings, C., Origoni, A., Schroeder, J., Khushalani, S., & Yolken, R. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt113 · Cited by 50
Metadata
- Authors
- Suvisaari, J., Partti, K., Perälä, J., Viertiö, S., Saarni, S. E., Lönnqvist, J., Saarni, S. I., & Härkänen, T.
- Venue
- Psychosomatic Medicine
- Published
- 2013-01
- Volume
- 75
- Issue
- 1
- Pages
- 60-67
- ISSN
- 0033-3174 (ISSN-L)
- OpenAlex
- W2315108796
- Cited by
- 63
- References
- 17
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.